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Background: Prostate smooth muscle contraction plays an important role for
pathophysiology and treatment of male lower urinary tract symptoms (LUTS) but is
incompletely understood. Because the efficacy of available medication is limited, novel
options and improved understanding of prostate smooth muscle contraction are of high
demand. Recently, a possible role of polo-like kinase 1 (PLK1) has been suggested for
smooth muscle contraction outside the lower urinary tract. Here, we examined effects
of PLK inhibitors on contraction of human prostate tissue.
Methods: Prostate tissues were obtained from radical prostatectomy. RT-PCR,
Western blot and immunofluorescence were performed to detect PLK expression
and phosphorylated PLK. Smooth muscle contractions were induced by electric field
stimulation (EFS), α1-agonists, endothelin-1, or the thromboxane A2 analog U46619 in
organ bath.
Results: RT-PCR, Western blot, and immunofluorescence suggested expression of
PLK1 in the human prostate, which may be located and active in smooth muscle cells.
EFS-induced contractions of prostate strips were reduced by SBE 13 (1 µM), cyclapolin
9 (3 µM), TAK 960 (100 nM), and Ro 3280 (100 nM). SBE 13 and cyclapolin 9 inhibited
contractions by the α1-agonists methoxamine, phenylephrine, and noradrenaline. In
contrast, no effects of SBE 13 or cyclapolin 9 on endothelin-1- or U46619-induced
contractions were observed.
Conclusion: Alpha1-adrenergic smooth muscle contraction in the human prostate can
be inhibited by PLK inhibitors. PLK-dependent signaling may be a new pathway, which
promotes α1-adrenergic contraction of prostate smooth muscle cells. As contractions
by endothelin and U46619 are not susceptible to PLK inhibition, this reflects divergent
regulation of adrenergic and non-adrenergic prostate smooth muscle contraction.
Keywords: benign prostatic hyperplasia (BPH), lower urinary tract symptoms (LUTS), prostate smooth muscle
contraction, α1-adrenoceptor, α1-blocker, polo-like kinase (PLK)
INTRODUCTION
Male lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH)
are commonly caused by bladder outlet obstruction (BOO), which is driven by increased
prostate smooth muscle tone and prostate growth (Caine et al., 1976; Hennenberg et al., 2014).
Induction of prostate smooth muscle relaxation is an important strategy for medical treatment
Frontiers in Physiology | www.frontiersin.org 1 June 2018 | Volume 9 | Article 734
fphys-09-00734 June 13, 2018 Time: 16:14 # 2
Hennenberg et al. PLK Inhibitors Inhibit Prostate Contraction
of voiding symptoms (Caine et al., 1976; Oelke et al., 2013;
Hennenberg et al., 2014). The most important option are
α1-adrenoceptor antagonists, as they may reduce symptoms by
inhibition of α1-adrenergic prostate smooth muscle contraction
and subsequent improvement of urethral obstruction and bladder
emptying (Caine et al., 1976; Oelke et al., 2013; Hennenberg et al.,
2014). However, their efficacy is limited, so that novel options and
better understanding of the regulation of prostate smooth muscle
contraction are required (Oelke et al., 2013; Hennenberg et al.,
2014, 2017).
For decades, it has been assumed that prostate smooth
muscle contraction is promoted by three intracellular signaling
pathways, including phospholipase C/IP3, diacylglycerol/protein
kinase C, and RhoA/Rho kinase, which are activated by
α1-adrenoceptors and by receptors for endothelin-1 and
thromboxane A2 (Christ and Andersson, 2007; Hennenberg
et al., 2014). This concept has been recently challenged, when it
became increasingly obvious, that much more signaling pathways
may be involved in promotion of prostate smooth muscle
contraction (Hennenberg et al., 2014). These may include several
GTPases and kinases, as smooth muscle contraction of the
human prostate was inhibited by inhibitors for RacGTPases, focal
adhesion kinases, p21-activated kinases, and src family kinases
(Kunit et al., 2014; Wang et al., 2015, 2016a,b). Together, this
suggested that mechanisms regulating or promoting prostate
smooth muscle contraction may be much more complex than
previously assumed.
Polo-like kinases (PLKs) are a group of serine-threonine
kinases, which have mostly been associated with regulation of cell
cycle and promotion of proliferation. In addition to this function,
recent studies suggested a role of PLK1 for contraction of airway
and vascular smooth muscle contraction (Li et al., 2016; de Carcer
et al., 2017). Moreover, several small molecule inhibitors for PLK1
have now become commercially available. Therefore, we here
studied the effects of PLK1 inhibitors on contraction of human
prostate tissue and possible expression of PLK1 in the human
prostate.
MATERIALS AND METHODS
Human Prostate Tissues
Human prostate tissues were obtained from patients (n = 157)
undergoing radical prostatectomy for prostate cancer. Patients
who underwent previous transurethral resection of the prostate
(TURP) were excluded. This study was carried out in accordance
with the Declaration of Helsinki of the World Medical
Association, and has been approved by the ethics committee
of the Ludwig Maximilian University of Munich, Munich,
Germany. Informed consent was obtained from all patients.
Samples and data were collected and analyzed anonymously.
Samples were taken immediately after prostatectomy, following
macroscopical examination by an uro-pathologist. All tissues
were taken from the periurethral zone, considering that most
prostate cancers arise in the peripheral zone (Pradidarcheep et al.,
2011; Shaikhibrahim et al., 2012). Upon pathologic evaluation,
only tissue samples which did not exhibit histological signs
of neoplasia, cancer, or inflammation were collected. BPH is
present in 80–83% of patients with prostate cancer (Alcaraz
et al., 2009; Orsted and Bojesen, 2013). The content of prostate-
specific antigen (PSA) increases with the degree of BPH, so
that varying PSA content (Figure 1) reflects divergent degree
of BPH in prostate samples from different patients (Levitt and
Slawin, 2007). For macroscopic examination and sampling, the
prostate was opened by a single longitudinal cut from the
capsule to the urethra. Subsequently, both intersections were
checked macroscopically for any obvious tumor infiltration.
Because tumors are usually located to the peripheral zone,
tumor infiltration in the periurethral zone (where sampling
was performed) was very rare (found in less than 1% of
prostates). Prostates showing tumors in the periurethral zone on
macroscopic inspection were not subjected to sampling and were
not included in this study. Organ bath studies were performed
immediately after sampling, while samples for molecular analyses
were shock frozen in liquid nitrogen and stored at−80◦C.
Real Time Polymerase Chain Reaction
(RT-PCR)
RNA from frozen prostate tissues or cells was isolated using the
RNeasy Mini kit (Qiagen, Hilden, Germany). For isolation from
tissues, 30 mg of tissue were homogenized using the FastPrep R©-24
system with matrix A (MP Biomedicals, Illkirch, France).
RNA concentrations were measured spectrophotometrically.
Reverse transcription to cDNA was performed with 1 µg of
isolated RNA using the Reverse Transcription System (Promega,
Madison, WI, United States). RT-PCR for PLK isoforms 1–5
and glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was
performed with a Roche Light Cycler (Roche, Basel, Switzerland)
using primers provided by Qiagen (Hilden, Germany) as
ready-to-use mixes, based on the RefSeq accession numbers
NM_005030 for PLK1, NM_001252226 for PLK2, NM_004073
for PLK3, NM_001190799 for PLK4, NM_001243079 for PLK5,
and NM_002046 for GAPDH. PCR reactions were performed
in a volume of 25 µl containing 5 µl LightCycler R© FastStart
DNA MasterPlus SYBR Green I (Roche, Basel, Switzerland),
1 µl template, 1 µl primer, and 18 µl water. Denaturation
was performed for 10 min at 95◦C, and amplification with 45
cycles of 15 s at 95◦C followed by 60 s at 60◦C. The specificity
of primers and amplification was demonstrated by subsequent
analysis of melting points, which revealed single peaks for each
target. Results were expressed using the 11CP method, where
number of cycles (Ct) at which the fluorescence signal exceeded
a defined threshold for GAPDH was subtracted from Ct values
for PLK (CtPLK-CtGAPDH = 1CP), and values were calculated as
2ˆ-1CP and normalized to each other.
Western Blot Analysis
Frozen prostate tissues were homogenized in a buffer containing
25 mM Tris/HCl, 10 µM phenylmethanesulfonyl fluoride, 1 mM
benzamidine, and 10 µg/ml leupeptine hemisulfate, using the
FastPrep R©-24 system with matrix A (MP Biomedicals, Illkirch,
France). After centrifugation (20,000 g, 4 min), supernatants were
assayed for protein concentration using the Dc-Assay kit (Biorad,
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FIGURE 1 | Detection of PLK in human prostate tissue. Analyses were performed by RT-PCR to detect mRNA of different PLK isoforms (A), or by Western blots to
detect putative PLK1 protein (B,C). Data in (A) are 11CP values [2ˆ-(Cttarget-CtGAPDH), normalized to each other] and median values (bar), from prostate tissues
from n = 7 patients. In (B), bands from all included samples are shown, with sizes matching the expected and indicated molecular weights of proteins. Western blot
analysis included calponin as a marker for smooth muscle cells, pan-cytokeratin as a marker of endothelial cells (glands), and prostate-specific antigen (PSA) as a
marker for benign prostatic hyperplasia. In (C), values (arbitrary units) after densitometric quantification of Western blots were plotted in diagrams, and subjected to
Spearman’s correlation analysis. In (D), correlation analysis for band intensities of PLK1 and PSA are shown.
Munich, Germany) and boiled for 10 min with sodium dodecyl
sulfate (SDS) sample buffer (Roth, Karlsruhe, Germany).
Samples (20 µg/lane) subjected to SDS-polyacrylamide
gel electrophoresis, and proteins were blotted on Protran
nitrocellulose R© membranes (Schleicher & Schuell, Dassel,
Germany). Membranes were blocked with phosphate-buffered
saline (PBS) containing 5% milk powder (Roth, Karlsruhe,
Germany) over night, and incubated with rabbit anti PLK1
(208G4) (#4513), rabbit anti phospho-PLK1 (threonine 210)
(#5472), mouse monoclonal anti pan-cytokeratin(sc-8018)
(Santa Cruz Biotechnology, Santa Cruz, CA, United States),
mouse monoclonal anti calponin 1/2/3 (sc-136987) (Santa
Cruz Biotechnology, Santa Cruz, CA, United States), mouse
monoclonal anti PSA (sc-7316) (Santa Cruz Biotechnology,
Santa Cruz, CA, United States), rabbit anti phospho-vimentin
(serine 56) (#3877), mouse anti vimentin (#3390), mouse anti
phospho-myosin light chain (MLC) 2 (serine 19) (#3675), rabbit
anti myosin light chan 2 (#8505), or mouse monoclonal anti
β-actin antibody (sc-47778) (Santa Cruz Biotechnology, Santa
Cruz, CA, United States) (if not other stated, from Cell Signaling
Technology, Danvers, MA, United States).
Primary antibodies were diluted in PBS containing 0.1%
Tween 20 (PBS-T) and 5% milk powder. Subsequently, detection
was continued using secondary biotinylated horse anti mouse
or horse anti goat IgG (BA-1000, BA-2000, BA-9500) (Vector
Laboratories, Burlingame, CA, United States), followed by
incubation with avidin and biotinylated horseradish peroxidase
(HRP) from the “Vectastain ABC kit” (Vector Laboratories,
Burlingame, CA, United States) both diluted 1:200 in PBS.
Membranes were washed with PBS-T after any incubation
with primary or secondary antibodies, or biotin-HRP. Finally,
blots were developed with enhanced chemiluminescence (ECL)
using ECL Hyperfilm (GE Healthcare, Freiburg, Germany).
Intensities of resulting bands for PLK1 and PSA were quantified
densitometrically using “Image J” (National Institutes of Health,
Bethesda, MD, United States), and values (arbitrary units)
were plotted against each other and subjected to Spearman’s
correlation analysis.
Immunofluorescence
Human prostate specimens, embedded in optimal cutting
temperature (OCT) compound, were snap-frozen in liquid
nitrogen and kept at −80◦C. Sections (8 µm) were cut in a
cryostat and collected on Superfrost R© microscope slides. Sections
were post-fixed in methanol at −20◦C and blocked in 1% bovine
serum albumin before incubation with primary antibody over
night at room temperature. For double labeling, the following
primary antibodies were used: rabbit anti PLK1 (208G4) (#4513)
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(Cell Signaling Technology, Danvers, MA, United States),
rabbit anti phospho-PLK1 (threonine 210) (#5472) (Cell
Signaling Technology, Danvers, MA, United States), mouse
anti pan-cytokeratin (sc-8018), or mouse anti calponin 1/2/3
(sc-136987) (if not other stated, from Santa Cruz Biotechnology,
Santa Cruz, CA, United States). Binding sites were visualized
using Cy3-conjugated goat anti mouse IgG (AP124C), fluorescein
isothiocyanate- (FITC-) conjugated rabbit anti goat IgG
(AP106F) (both from Millipore, Billerica, MA, United States,
and Cy5-conjugated goat anti rabbit IgG (ab6564) (Abcam,
Cambridge, United Kingdom). Nuclei were counterstained
with 4′,6′-diamidino-2-phenylindole-dihydrochloride (DAPI)
(Invitrogen, Camarillo, CA, United States). Immunolabeled
sections were analyzed using a laser scanning microscope
(Leica SP2, Wetzlar, Germany). Fluorescence was recorded with
separate detectors. Control stainings without primary antibodies
did not yield any signals.
Tension Measurements
Prostate strips (6 × 3 × 3 mm) were mounted in 10 ml aerated
(95% O2 and 5% CO2) tissue baths (Danish Myotechnology,
Aarhus, Denmark), containing Krebs–Henseleit solution (37◦C,
pH 7.4) with following composition: 118 mM NaCl, 4.7 mM
KCl, 2.55 mM CaCl2, 1.2 mM KH2PO4, 1.2 mM MgSO4, 25 mM
NaHCO3, 7.5 mM glucose. In each single experiment, four strips
were obtained from the same prostate, and allocated to both
the control (without inhibitor) and inhibitor group (two strips
per group, resulting in duplicate determination for each group
in each single experiment). Consequently, control and inhibitor
curves in each diagram were obtained from the same prostates,
but different prostates were examined for different diagrams.
Therefore, and considering that prostate tissues from radical
prostatectomy may show considerable heterogeneity (as shown in
the results section), statistical comparisons were only performed
between groups within the same series (i.e., containing tissues
from the same prostates for inhibitor and control group), but
not between series obtained from different prostates (i.e., not
across different series of organ bath experiments). The amount
of solvent differed between series, due to divergent inhibitor
concentrations (100 nM, 1 µM, 3 µM). Again, this precludes any
comparison between contraction levels in different series. Only
one curve was recorded with each sample (agonist or EFS, either
with DMSO or inhibitor).
After mounting in organ bath chambers, preparations were
stretched to 4.9 mN and left to equilibrate for 45 min. In the
initial phase of the equilibration period, spontaneous decreases
in tone are usually observed. Therefore, tension was adjusted
three times during the equilibration period, until a stable
resting tone of 4.9 mN was attained. After the equilibration
period, maximum contraction induced by 80 mM KCl was
assessed. Subsequently, chambers were washed three times with
Krebs–Henseleit solution for a total of 30 min. Cumulative
concentration response curves for noradrenaline, phenylephrine,
methoxamine, endothelin-1, and for U46619, or frequency
response curves induced by electric field stimulation (EFS) were
created 30 min after addition of SBE 13 (1 µM), cyclapolin 9
(3 µM), or dimethylsulfoxide (DMSO) for controls. Application
of EFS simulates action potentials, resulting in the release of
endogenous neurotransmitters, including norepinephrine. Using
the inhibitor for neurotransmitter release, tetrodotoxin, it has
been previously demonstrated, that this accounts for two-thirds
of EFS-induced contraction in the human prostate (Angulo et al.,
2012). For EFS, tissue strips were placed between two parallel
platinum electrodes connected to a Grass S48 stimulator (Danish
Myotechnology, Denmark). Square pulses with durations of 1 ms
were applied with a voltage of 50 V, for a train duration of 10 s
and using a delay of 1 ms between single pulses. EFS-induced
contractile responses were studied at frequencies of 2, 4, 8, 16,
and 32 Hz, with train intervals of 30 s between stimulations.
For calculation of agonist- or EFS-induced contractions,
tensions (peak height in EFS-induced contractions and
maximum contractions following agonist-exposure) were
expressed as % of KCl-induced contractions, as this may correct
different stromal/epithelial ratios, different smooth muscle
content, varying degree of BPH, or any other heterogeneity
between prostate samples and patients. As KCl-induced
contractions were assessed before application of PLK inhibitors,
effects of inhibitors can be seen despite diverging expression
levels of PLK1.
Phosphorylation Studies
Tissues from each included prostate were cut into several small
strips (6 × 1 × 1 mm), which were then allocated to two
or three samples (control group and agonist group, or one
control group and two inhibitor groups). Consequently, all series
had identical group sizes, and in each single experiment, tissue
from the same patient was used for all groups. Incubation of
samples with inhibitors, agonists and solvent (controls) was
performed in 6-well plates filled with custodiol solution. After an
equilibration period of 20 min, inhibitors, agonists and solvent
were added, and plates were kept at 37◦C under continuous
shaking for indicated periods. Therefore, samples of the control
groups were kept under experimental conditions for the same
periods as their corresponding agonist or inhibitor groups.
Following incubations, tissues were shock frozen with liquid
nitrogen, and subjected to Western blot analysis for phospho-
PLK, PLK, phospho-vimentin, vimentin, phospho-MLC, MLC,
or β-actin. Each setting was repeated in several independent
experiments using different prostates, to obtain groups sizes
as indicated. Intensities of resulting bands were quantified
densitometrically using “Image J” (National Institutes of Health,
Bethesda, MD, United States). For semiquantitative calculation,
values of each sample were normalized to the mean of the
corresponding control group, so that agonist and inhibitor
groups are expressed as percent (%) of the corresponding control
group.
Drugs and Nomenclature
N-[[4-[(6-Chloro-3-pyridinyl)methoxy]-3-methoxyphenyl]me-
thyl]-3,4-dimethoxybenzeneethanamine hydrochloride (SBE 13),
7-Nitro-5-(trifluoromethyl)-2-benzothiazolecarboxamide-3-oxi-
de (cyclapolin 9), 4-[(9-Cyclopentyl-7,7-difluoro-6,7,8,9-tetra-
hydro-5-methyl-6-oxo-5H-pyrimido[4,5-b][1,4]diazepin-2-yl)
amino]-2-fluoro-5-methoxy-N-(1-methyl-4-piperidinyl)benza-
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mide hydrochloride (TAK 960), and 4-[(9-Cyclopentyl-7,7-di-
fluoro-6,7,8,9-tetrahydro-5-methyl-6-oxo-5H-pyrimido[4,5-b]
[1,4]diazepin-2-yl)amino]-3-methoxy-N-(1-methyl-4-piperidi-
nyl) benzamide (Ro 3280) are selective PLK1 inhibitors. Stock
solutions (10 mM) were prepared in DMSO, and stored at
−20◦C until use. Phenylephrine ((R)-3-[-1-hydroxy-2-(meth-
ylamino)ethyl]phenol) and methoxamine (α-(1-Aminoethyl)-
2,5-dimethoxybenzyl alcohol) are selective agonists for
α1-adrenoceptors. U46619 ((Z)-7-[(1S,4R,5R,6S)-5-[(E,3S)-
3-hydroxyoct-1-enyl]-3-oxabicyclo[2.2.1]heptan-6-yl]hept-5-
enoic acid) is an analog of thromboxane A2 (TXA2) and
frequently used as an agonist for thromboxane A2 receptors.
Aqueous stock solutions of phenylephrine and noradrenaline
(10 mM) were freshly prepared before each experiment. Stock
solutions of U46619 were prepared in ethanol, and stored
at −80◦C until use. Aqueous stock solutions of endothelin-
1 were stored at −20◦C until used. SBE 13, cyclapolin 9,
TAK 960, Ro 3280, and U46619 were obtained from Tocris
(Bristol, United Kingdom), phenylephrine, methoxamine, and
noradrenaline were obtained from Sigma (Munich, Germany),
and endothelin-1 from Enzo Life Sciences (Lörrach, Germany).
Statistical Analysis
Data are presented as means± standard error of the mean (SEM)
with the indicated number (n) of experiments. One-way analysis
of variance (ANOVA) and multivariate ANOVA were used for
paired or unpaired observations. P-values< 0.05 were considered
statistically significant.
RESULTS
Detection of PLK1 in Human Prostate
Tissues
By RT-PCR, mRNAs for all five PLK isoforms were detectable
in human prostate tissues (Figure 1A). The content of mRNA
for PLK isoforms 1-4 varied considerably between different
prostates (Figure 1A). As a role in smooth muscle contraction
may only be supposed for PLK1, Western blot analysis was
performed for PLK1. Detection with an antibody raised against
PLK1 revealed bands with sizes matching the expected molecular
weight of PLK1, while other bands were almost completely
absent (Figure 1B). These bands were observed in each prostate
sample included in this analysis, despite obvious variations in
intensity between bands obtained with samples from different
patients (Figure 1C). Following semiquantitative evaluation of
bands, correlation analysis was performed for PLK1 and PSA. No
correlation was observed between intensities of assumed PLK1
and PSA bands (R =−0.024) (Figure 1D).
Immunofluorescence stainings were performed using
antibodies raised against PLK1 and phospho-PLK1 (threonine
210). Similar to the antibody raised against PLK1, the antibody
raised against phospho-PLK1 revealed bands with sizes matching
the expected molecular weight of PLK1, while other bands were
lacking (Figure 1B). Most samples of prostate tissue showed the
typical architecture, composed of stroma with calponin-positive
smooth muscle cells, and glands with pan-cytokeratin-positive
epithelial cells (Figure 2). In addition to the typical architecture,
some parts were characterized by large areas without glands and
contained only stroma and predominantly calponin-positive
cells (Figure 2). Immunoreactivity for the PLK1 antibody
was observed in the stroma and in glands (Figure 2). In the
stroma, PLK1 immunoreactivity was strong and colocalized with
calponin in both types of prostate tissue, suggesting localization
of this immunoreactivity in smooth muscle cells of areas
with normal architecture, and in areas with extended stroma
(Figure 2). In glands, immunoreactivity for PLK1 colocalized
with pan-cytokeratin, suggesting localization in the glandular
epithelium (Figure 2).
Immunoreactivity for the phospho-PLK1 antibody was
observed in the stroma, where it was ubiquitous and strong,
and to a limited degree in glands (Figure 3). There was
immunoreactivity for phospho-PLK1 colocalized with calponin
in the stroma, suggesting the presence of active PLK1 in
smooth muscle cells (Figure 3). Colocalization of phospho-PLK1
immunoreactivity with pan-cytokeratin was observed in some,
but not all glands (Figure 3).
Effects of SBE 13, Cyclapolin 9, TAK 960,
and Ro 3280 on EFS-Induced
Contractions
EFS (2–32 Hz) induced frequency-dependent contractions of
prostate strips, which were inhibited by SBE 13 (1 µM),
cyclapolin 9 (3 µM), TAK 960 (100 nM), and Ro 3280 (100 nM)
(Figure 4). Two-way ANOVA was conducted to compare
inhibitor and control groups, and indicated that the inhibition by
SBE 13 (p < 0.02), cyclapolin 9 (p < 0.03), TAK 960 (p < 0.007),
and Ro 3280 (p < 0.04) was significant. Multivariate analysis
revealed that inhibition was significant for all four inhibitors at
least at 32 Hz (Figure 4).
Effects of SBE 13 and Cyclapolin 9 on
Methoxamine-Induced Contractions
Methoxamine (0.1–100 µM) induced concentration-dependent
contractions of prostate strips, which were inhibited by SBE
13 (1 µM) and cyclapolin 9 (3 µM) (Figure 5). Two-way
ANOVA was conducted to compare inhibitor and control groups,
and indicated that the inhibition by SBE 13 (p < 0.002) and
cyclapolin 9 (p < 0.02) was significant. Multivariate analysis
revealed that inhibition by SBE 13 was significant at 10–100 µM
of methoxamine, and by cyclapolin 9 at 100 µM of methoxamine
(Figure 5).
Effects of SBE 13 and Cyclapolin 9 on
Phenylephrine-Induced Contractions
Phenylephrine (0.1–100 µM) induced concentration-dependent
contractions of prostate strips, which were inhibited by SBE
13 (1 µM) and cyclapolin 9 (3 µM) (Figure 5). Two-way
ANOVA was conducted to compare inhibitor and control groups,
and indicated that the inhibition by SBE 13 (p < 0.002) was
significant. Multivariate analysis revealed that inhibition by SBE
13 was significant at 3–100 µM of phenylephrine (Figure 5).
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FIGURE 2 | Immunofluorescence staining for PLK1 of human prostate tissues. Sections were double labeled with antibodies for PLK1, calponin (marker for smooth
muscle cells) or pan-cytokeratin (marker for glandular epithelial cells). Yellow color in merged pictures indicates colocalization of targets. Shown are representative
stainings from series with tissues from n = 5 patients for each combination, performed with tissues showing typical architecture composed of glands and stroma,
and a tissue from an extended stromal area showing only calponin-positive smooth muscle cells but no glands (upper panel, right image). Negative controls were
performed without primary antibodies but Cy3- and Cy5-coupled secondary antibodies (lower panel, right image).
Effects of SBE 13 and Cyclapolin 9 on
Noradrenaline-Induced Contractions
Noradrenaline (0.1–100 µM) induced concentration-dependent
contractions of prostate strips, which were inhibited by SBE 13
(1 µM) and cyclapolin 9 (3 µM) (Figure 5). Two-way ANOVA
was conducted to compare inhibitor and control groups, and
indicated that the inhibition by SBE 13 (p < 0.01) and cyclapolin
9 (p < 0.002) was significant. Multivariate analysis revealed that
inhibition by cyclapolin 9 was significant at 30 and 100 µM of
noradrenaline (Figure 5).
Effects of SBE 13 and Cyclapolin 9 on
Endothelin-1-Induced Contractions
Endothelin-1 (0.1–3 µM) induced concentration-
dependent contractions of prostate strips (Figure 6).
Two series of experiments did not provide a basis
to assume that SBE 13 (1 µM) or cyclapolin 9
(3 µM) may inhibit endothelin-1-induced contractions
(Figure 6), so that these exploratory series were not
continued after three independent experiments in each
series.
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FIGURE 3 | Immunofluorescence staining for phospho-PLK1 of human prostate tissues. Sections were double labeled with antibodies for phospho-PLK1 (threonine
210), calponin (marker for smooth muscle cells) or pan-cytokeratin (marker for glandular epithelial cells). Yellow color in merged pictures indicates colocalization of
targets. Shown are representative stainings from series with tissues from n = 5 patients for each combination, and examples with and without glandular
colocalization of phospho-PLK1 with pan-cytokeratin (lower panels). Negative controls were performed without primary antibodies but Cy3- and Cy5-coupled
secondary antibodies (upper panel, right image).
Effects of SBE 13 and Cyclapolin 9 on
U46619-Induced Contractions
U46619 (0.1–30 µM) induced concentration-dependent
contractions of prostate strips (Figure 6). SBE 13 (1 µM) and
cyclapolin 9 (3 µM) did not alter U46619-induced contractions
(Figure 6).
Effects of Contractile Agonists on PLK
Phosphorylation
Incubation of prostate tissues with methoxamine (30 µM) for
10 or 30 min, with noradrenaline (30 µM) for 30 min, or with
U46619 (30 µM) for 60 min did not change the average content
of phospho-PLK (threonine 210) or total PLK (Figure 7).
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FIGURE 4 | Effects of SBE 13 (1 µM), cyclapolin 9 (3 µM), TAK 960 (100 nM), and Ro 3280 (100 nM) on EFS-induced prostate contractions. In an organ bath,
contractions of human prostate strips were induced by EFS. Effects of inhibitors on contractions were compared with corresponding controls (DMSO) in separate
sets of experiments. To eliminate heterogeneities including any individual variations, different degree of BPH, or varying smooth muscle content (compare Figure 1),
tensions have been expressed as % of highmolar KCl-induced contraction, which was assessed before application of inhibitors or solvent. Data are means ± SEM
from series with tissues from n = 7 patients/group for SBE 13, n = 7 patients/group for cyclapolin 9, n = 7 patients/groups for TAK 960, and n = 10 patients/group
for Ro 3280. For each diagram, samples from each patient were allocated to both the control and inhibitor groups, so that both groups in each diagram are obtained
from the same tissues (∗p < 0.05 for control vs. inhibitor).
Effects of PLK Inhibitors on
Phosphorylation of Vimentin and MLC
Incubation of prostate tissues with SBE 13 (1 µM), cyclapolin
9 (3 µM), Ro 3280 (100 nM), or TAK 960 (100 nM) for
60 min reduced the average content of phospho-vimentin (serine
56). This was significant for Ro 3280 (p < 0.05) and TAK960
(p< 0.009), while a trend was observed for SBE 13 and cyclapolin
9 (Figure 8). In contrast, none of the inhibitors changed the
content of total vimentin, phospho-MLC (serine 19), or MLC
(Figure 8).
DISCUSSION
Our findings suggest that neurogenic and α1-adrenergic smooth
muscle contraction in the human prostate can be inhibited
by PLK inhibitors. In contrast to α1-adrenergic contractions,
endothelin-1- and thromboxane A2-induced contractions were
not susceptible to PLK inhibitors, pointing to a divergent
regulation of adrenergic and non-adrenergic prostate smooth
muscle contraction by PLKs. It appears possible that PLK1
promotes α1-adrenergic smooth muscle contractions in the
hyperplastic human prostate. This is in line with recent evidence,
which suggested that smooth muscle contraction of the human
prostate is insufficiently understood. In fact, recent studies
reported inhibition of prostate smooth muscle contraction by
inhibitors for several kinases or GTPases (including c-Jun
N-terminal kinase, focal adhesion kinase, src family kinases, LIM
kinases, Rac GTPases) (Strittmatter et al., 2012; Kunit et al.,
2014; Wang et al., 2016a,b; Herlemann et al., 2018; Yu et al.,
2018), although their involvement of prostate smooth muscle
contraction was not known before. This demonstrates that this
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FIGURE 5 | Effects of SBE 13 (1 µM) and cyclapolin 9 (3 µM) on α1-adrenoceptor-induced prostate contractions. In an organ bath, contractions of human prostate
strips were induced by the α1-adrenoceptor agonists methoxamine, phenylephrine, or noradrenaline. Effects of inhibitors on contractions were compared with
corresponding controls (DMSO) in separate sets of experiments. To eliminate heterogeneities including any individual variations, different degree of BPH, or varying
smooth muscle content (compare Figure 1), tensions have been expressed as % of highmolar KCl-induced contraction, which was assessed before application of
inhibitors or solvent. Data are means ± SEM from series with tissues from n = 10 patients/group for noradrenaline/SBE 13, n = 5 patients/group for
noradrenaline/cyclapolin 9, n = 5 patients/group for methoxamine/SBE 13, n = 13 patients/group for methoxamine/cyclapolin 9, n = 8 patients/group for
phenylephrine/SBE 13, and n = 9 patients/group for phenylephrine/cyclapolin 9. For each diagram, samples from each patient were allocated to both the control and
inhibitor groups, so that both groups in each diagram are obtained from the same tissues (∗p < 0.05 for control vs. inhibitor).
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FIGURE 6 | Effects of SBE 13 (1 µM) and cyclapolin 9 (3 µM) on non-adrenergic prostate contractions. In an organ bath, contractions of human prostate strips were
induced by endothelin-1, or by the thromboxane A2 analog U46619. Effects of inhibitors on contractions were compared with corresponding controls (DMSO) in
separate sets of experiments. To eliminate heterogeneities including any individual variations, different degree of BPH, or varying smooth muscle content (compare
Figure 1), tensions have been expressed as % of highmolar KCl-induced contraction, which was assessed before application of inhibitors or solvent. Data are
means ± SEM from series with tissues from n = 3 patients/group for endothelin-1/SBE 13, n = 3 patients/groups for endothelin-1/cyclapolin 9, n = 9 patients/group
for U46619/SBE 13, and n = 6 patients/group for U46619/cyclapolin 9. For each diagram, samples from each patient were allocated to both the control and inhibitor
groups, so that both groups in each diagram are obtained from the same tissues.
process is probably more complex than previously assumed, what
may be important from a clinical point of view. Considering the
insufficient efficacy of available medications for LUTS treatment,
the important role of prostate smooth muscle tone for etiology
and therapy of male LUTS, together with the high and even
increasing relevance of LUTS, proves our understanding of
regulation of smooth muscle contraction in the lower urinary
tract is in fact highly mandatory to overcome current limitations
in future.
Following the discovery of PLK1 as important regulator of
mitosis and proliferation in different cell types, PLKs emerged
as promising new targets in oncology (McInnes et al., 2005).
This initiated the development of PLK-specific small molecule
inhibitors, which has been promoted during the last decade and
resulted in several inhibitors which are now available for research
purposes (Gutteridge et al., 2016). In kinase assays based on
immunoprecipitated enzymes, SBE 13 showed high selectivity for
PLK1, with an IC50 value of 200 pM for PLK1 inhibition, and
IC50 values of 66 µM and 875 nM for inhibition of PLK2 and
−3, while no inhibition of aurora kinase was observed (Keppner
et al., 2009, 2010). In different cell lines, including HeLa and
cancer cells, proliferation was inhibited with EC50 values ranging
between 5 and 60 µM (Keppner et al., 2009, 2010). Cyclapolin
9 showed an IC50 of 500 nM for PLK1 in in vitro kinase assays,
while a panel of at least 37 other kinases was not inhibited even at
a cyclapolin 9 concentration of 100µM (McInnes et al., 2006). Ro
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FIGURE 7 | Effects of contractile agonists on PLK phosphorylation. Prostate tissues were stimulated with different agonists and for different periods in separate sets
of experiments. Subsequently, PLK phosphorylation at threonine 210 was compared between stimulated samples and corresponding controls (exposed to identical
experimental conditions) by Western blot analysis using a phospho-specific antibody. Stimulation was performed with the α1-adrenoceptor agonist methoxamine
(30 µM) for 10 or 30 min, with noradrenaline (30 µM) for 15 min, or with the thromboxane A2 analog U46619 (30 µM) for 60 min. In each series, tissues in the
agonist and corresponding control group were obtained from the same prostates. Shown are representative Western blots and quantification of all experiments, from
series with n = 4 patients for methoxamine 10 min, n = 4 patients for methoxamine 30 min, n = 5 patients for noradrenaline 15 min, and n = 6 patients for
noradrenaline 60 min.
3280 inhibited PLK1 with an IC50 value of 3 nM in biochemical
assays, and 6 nM in H82 cells (Chen et al., 2012). Even at a
concentration of 1 µM, Ro 3280 inhibited only 13 out of a panel
of 293 tested kinases (Chen et al., 2012). EC50 values for the
inhibition of proliferation in 13 different tumor cell lines ranged
between 6 and 82 nM, with 12 nM for prostatic PC-3 cells (Chen
et al., 2012). TAK-960 inhibits PAK1 with an IC50 of 1.5–2 nM,
and is orally available (Hikichi et al., 2012; Nie et al., 2013).
Proliferation of cultured cancer cells was effectively inhibited by
TAK-960 in a low, one-digit nanomolar range (Nie et al., 2013).
At a concentration of 1 µM, 243 of 288 tested kinases were
inhibited by less than 20% (Hikichi et al., 2012). Therefore and
based on the concentrations used in our study (1 µM SBE 13;
3 µM cyclapolin 9; 100 nM Ro 3280; 100 nM TAK-960), we
assume that the effects we observed in our experiments using
human prostate tissues may be attributed largely to inhibition of
PLKs, while unspecific kinase inhibition may play a minor role.
In addition to our functional experiments with PLK inhibitors
in an organ bath, the presence of active PLK1 in smooth
muscle cells of human prostate tissues was suggested by
molecular detection. Staining with an antibody for threonine-
210-phosphorylated PLK1 resulted in immunoreactivity within
stromal smooth muscle cells. Activation of PLK1 requires
phosphorylation at this residue, so that this may reflect the
presence of active PLK1 (Jang et al., 2002; Paschal et al., 2012).
Detection by RT-PCR and Western blot analysis suggested that
PLK1 and other isoforms may be present in all analyzed tissues,
despite strong variations in expression level. Because a role for
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FIGURE 8 | Effects of PLK inhibitors on phosphorylation of vimentin and MLC. Prostate tissues were incubated with PLK inhibitors and equivalent amounts of
solvent (DMSO) for 60 min. Two sets of experiments were performed, where effects of SBE 13 (1 µM) and cyclapolin 9 (3 µM), or of Ro 3280 (100 nM) and TAK 960
(100 nM) were assessed. Vimentin phosphorylation at serine 56 and MLC phosphorylation at serine 19 were compared between inhibitor-treated samples and
corresponding controls (exposed to identical experimental conditions) by Western blot analysis using phospho-specific antibodies. In each series, tissues in the
agonist and corresponding control group were obtained from the same prostates. Shown are representative Western blots and quantification of all experiments, from
series with n = 8 patients the SBE 13/cyclapolin 9 series, and n = 8 other patients for the Ro 3280/TAK960 series (∗p < 0.05 for control vs. inhibitor).
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smooth muscle contraction may be suspected for PLK1, but
not for other isoforms, we confined our Western blot analyses
and fluorescence stainings to PLK1 (Li et al., 2016; de Carcer
et al., 2017). Our findings may suggest that PLK1 is expressed in
prostate tissues from all examined patients, while the expression
level varied independently from BPH. This became obvious from
correlation analysis including band intensities of assumed PLK1
and PSA bands. PSA was detectable in all samples with varying
content, reflecting different degree of BPH in prostates from
different patients. Consequently, our tissues may be regarded
as hyperplastic, although the degree of BPH may vary. From a
clinical point of view, only the hyperplastic state is of relevance,
as male LUTS are usually associated with BPH. Previously,
numerous studies addressed the role of PLKs for proliferation of
prostate cancer cells and for tumor growth in the prostate, while
the present study may be the first suggesting expression and a
function of PLK1 in non-malignant prostate tissue (Liu et al.,
2011; Wissing et al., 2013).
The use of antibodies may be regarded as a possible limitation.
In fact, antibodies used in our Western blot analyses and stainings
were not validated, so that these results should be considered
with care. On the other hand, we only considered bands with
sizes matching the expected molecular weight of PLK1. Moreover,
our functional and molecular data may confirm each other.
Thus, despite several limitations, our data may strongly suggest
the presence of PLKs and a role in promotion of smooth
muscle regulation in the human prostate, if all of our findings
are regarded together. Notably, we observed inhibition of
α1-adrenergic and EFS-induced contractions by PLK inhibitors
despite high variation of PLK1 expression between different
prostate tissues, which was suggested by Western blot analyses.
This may underline the importance of PLK for regulation of
prostate smooth muscle contraction. We used different inhibitors
and different agonists, so that the data may confirm each other
and that the findings may be valid despite all heterogeneities or
despite divergent PLK expression.
Recent studies addressed the role of PLK1 in contraction
of airway and vascular smooth muscle. First, contraction of
tracheal rings from knock out mice was reduced in organ bath
experiments, and reduced airway constriction was observed
in vivo (Li et al., 2016). More recently, a role of PLK1 for
contraction of vascular smooth muscle has been suggested, again
using PLK1-deficient mice (de Carcer et al., 2017). In vivo, these
mice showed hypotension, and reduced angiotensin II-induced
hypertension (de Carcer et al., 2017). In organ bath studies,
contractile responses to α1-agonists and angiotensin II were
reduced in the aorta and in mesenteric arteries from PLK1
knock-out mice (de Carcer et al., 2017). Together, these findings
prompted us to examine possible effects of PLK inhibitors on
prostate smooth muscle contraction.
The role of PLK for promotion of smooth muscle contraction
is obviously shared by the prostate, the cardiovascular system
and airways (Li et al., 2016; de Carcer et al., 2017). Our findings
may point to divergent regulation of PLK activity in different
organs, but to shared mechanism underlying this PLK function.
Unlike airway smooth muscle, where PLK may be activated by
stimulation of cholinergic receptors during acetylcholin-induced
contraction (Li et al., 2016), PLK is apparently not activated by
contractile receptors in the human prostate. We tested different
incubation periods with agonists, considering that kinetics of
contraction may differ for α1-adrenoceptor agonists and U46619.
Although our data suggest active PLK1 in resting prostate smooth
muscle, the activating mechanisms remain to be determined and
may not be concluded from our present study. On the other hand,
intracellular mechanisms underlying PLK-dependent promotion
of smooth muscle contraction may be similar in the prostate
and airways. Similar to airway smooth muscle, our findings
suggest that a mechanism based on vimentin phosphorylation at
serine 56 may underly promotion of smooth muscle contraction
by PLK in the prostate, while an involvement of myosin light
chain (MLC) phosphorylation appears unlikely. In fact, vimentin
promotes smooth muscle contraction independently from MLC
phosphorylation (Wang et al., 2006; Li et al., 2016). Although
our findings addressing intracellular mechanisms of PLK actions
in prostate smooth muscle contraction are to some extent still
preliminary, this may provide a basis for further investigations,
including the role of vimentin in prostate smooth muscle
cells.
Worldwide, 600 million patients with LUTS suggestive of
BPH are expected in 2018, paralleled by expenses of probably
more than 4.7 billion USD for medical treatment of male
LUTS (Irwin et al., 2011; Ventura et al., 2011). Case numbers,
expenses, and relevance of LUTS will even further increase,
because the prevalence of LUTS increases with age and due to
the demographic transition at least in Western countries. This is
contrasted by the limited efficacy of available drugs to improve
urinary flow (Qmax) or international prostate symptom scores
(IPSS) by not more than 50% (Oelke et al., 2013; Hennenberg
et al., 2014, 2017). In fact, disappointing results of medical LUTS
therapy contributes to exceedingly high discontinuation rates,
peaking up to 70% of patients discontinuing their medication
within 12 month following first prescription (Cindolo et al.,
2015). This may result in disease progression, hospitalization,
and surgery for BPH (Cindolo et al., 2015). Considering all this
together with the role of prostate smooth muscle contraction
for pathophysiology and therapy of male LUTS, improved
understanding of prostate smooth muscle contraction becomes
increasingly important.
Our current findings are in line with recent studies suggesting
that the contractile mechanisms of prostate smooth muscle are
incompletely understood. For more than one decade, it has been
assumed that prostate smooth muscle contraction is promoted
by three intracellular signaling pathways, including inositol-
1,4,5-trisphosphate/calcium, diacylglycerol/protein kinase C, and
RhoA/Rho kinase (Andersson et al., 1997; Christ and Andersson,
2007). It has now become clear, that mechanisms of prostate
smooth muscle contraction are much more complex and
encompass further pathways and mediators, including several
kinases, GTPases, and their activators (Strittmatter et al., 2011;
Kunit et al., 2014; Wang et al., 2015, 2016a,b). Our current
findings suggest that the network of procontractile signaling
pathways in the prostate includes PLKs. This ongoing, recent
discovery of new contraction mechanisms in the prostate is
paralleled by research in other organs, being characterized by
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a similar continuous description of new mediators of smooth
muscle contraction.
Non-adrenergic mediators, particularly endothelin-1 and
thromboxane A2, may contribute to prostate smooth muscle
contraction in parallel to α1-adrenoceptors. It is assumed
that their contributions to prostate smooth muscle tone are
responsible for the limitations of α1-blockers, as they will
not inhibit endothelin- or thromboxane-induced contractions
and may improve LUTS by maximally 50% (Hennenberg
et al., 2013, 2014, 2017). The importance of these non-
adrenergic mediators for prostate smooth muscle tone has
recently become clear (Hennenberg et al., 2013, 2014, 2017;
Strittmatter et al., 2011). Due to the assumed high relevance
of non-adrenergic mediators for etiology and therapy of
LUTS suggestive of BPH, adequate understanding of their
contractile mechanisms may be very much appreciated. However,
compared to α1-adrenergic prostate contraction, they are less
understood and only little is known about the underlying
mechanisms. Certainly, adrenergic and non-adrenergic prostate
contraction share some common intracellular pathways, e.g.,
signaling by calcium and Rho kinase, which are used by α1-
adrenoceptors, as well as thromboxane and endothelin receptors
to induce smooth muscle contraction in the prostate (Christ
and Andersson, 2007; Takahashi et al., 2007; Strittmatter et al.,
2011). However, our present study demonstrates that adrenergic
and non-adrenergic contractions may be differentially promoted
and regulated, apart from shared intracellular mechanisms
of receptor-induced contraction. Obviously, a PLK inhibitor-
sensitive mechanism confers differential regulation of α1-
adrenergic and non-adrenergic prostate contraction in the
human prostate. Understanding such differences is mandatory to
grasp regulation and mechanisms of non-adrenergic contraction
in the context of LUTS treatment, and to address it in future
therapies.
CONCLUSION
Alpha1-adrenergic smooth muscle contraction in the human
prostate can be inhibited by PLK inhibitors. PLK-dependent
signaling may be a new pathway, which promotes contraction
of prostate smooth muscle cells. As contractions by endothelin
and thromboxane A2 are not susceptible to PLK inhibition,
this reflects differences in promotion of adrenergic and non-
adrenergic prostate smooth muscle contraction.
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